126 related articles for article (PubMed ID: 20648030)
1. Regulatory challenges, reimbursement, and risk-benefit assessment.
Breckenridge A
Clin Pharmacol Ther; 2010 Aug; 88(2):153-4. PubMed ID: 20648030
[No Abstract] [Full Text] [Related]
2. Drug safety special: chasing shadows.
Frantz S
Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
[No Abstract] [Full Text] [Related]
3. International pharmaceutical social risk regulation: An ethical perspective.
Gordon C
Acta Pharm; 2011 Mar; 61(1):15-23. PubMed ID: 21406340
[TBL] [Abstract][Full Text] [Related]
4. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
5. Patents: a threat to innovation?
Manocaran M
Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
[No Abstract] [Full Text] [Related]
6. Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics.
Califf RM;
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):5-16. PubMed ID: 16506270
[TBL] [Abstract][Full Text] [Related]
7. This pill washes whiter.
Fricker J
New Sci; 1998 Oct. 31; 160(2158):22-33. PubMed ID: 11657751
[No Abstract] [Full Text] [Related]
8. New rules for US drug reimbursement.
Bouchie A
Nat Biotechnol; 2003 Oct; 21(10):1119-20. PubMed ID: 14520382
[No Abstract] [Full Text] [Related]
9. Industry and regulatory performance in 2012: a year in review.
Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
[TBL] [Abstract][Full Text] [Related]
10. Medicines regulation and health technology assessment.
Breckenridge A; Woods K; Walley T
Clin Pharmacol Ther; 2010 Feb; 87(2):152-4. PubMed ID: 20107448
[TBL] [Abstract][Full Text] [Related]
11. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.
Eichler HG; Pignatti F; Flamion B; Leufkens H; Breckenridge A
Nat Rev Drug Discov; 2008 Oct; 7(10):818-26. PubMed ID: 18787530
[TBL] [Abstract][Full Text] [Related]
12. The challenges of immunogenicity in developing biosimilar products.
Wadhwa M; Thorpe R
IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
[TBL] [Abstract][Full Text] [Related]
13. Pharma faces major challenges after a year of failures and heated battles.
Frantz S
Nat Rev Drug Discov; 2007 Jan; 6(1):5-7. PubMed ID: 17269157
[No Abstract] [Full Text] [Related]
14. Incentives aim to boost antibiotic development.
Roberts JP
Nat Biotechnol; 2012 Aug; 30(8):735. PubMed ID: 22871701
[No Abstract] [Full Text] [Related]
15. The people vs patents.
New Sci; 2002 Jul; 175(2351):3. PubMed ID: 12625337
[No Abstract] [Full Text] [Related]
16. Deals landscape: notable deals in the pharmaceutical industry in the second quarter of 2008.
Bright J; Lakeram M
IDrugs; 2008 Aug; 11(8):584-91. PubMed ID: 18724496
[No Abstract] [Full Text] [Related]
17. [Safety assessment of new products developed by the pharmaceutical industry].
Claude JR
Ann Pharm Fr; 2001 Sep; 59(5):324-30. PubMed ID: 11787426
[TBL] [Abstract][Full Text] [Related]
18. Vendor competition, generic drugs spur drop in pharmaceutical prices.
Seigner CA
Mod Healthc; 1985 Oct; 15(21):56, 60-2. PubMed ID: 10317662
[No Abstract] [Full Text] [Related]
19. The pharmaceutical industry--to whom is it accountable?
Summers WK; Driscoll J; Orient JM
N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183883
[No Abstract] [Full Text] [Related]
20. China's deadly drug problem.
Cyranoski D
Nature; 2007 Apr; 446(7136):598-9. PubMed ID: 17410150
[No Abstract] [Full Text] [Related]
[Next] [New Search]
